Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies
Objective: Immunotherapy against α-synuclein is a promising novel treatment strategy for Parkinson's disease and related α-synucleinopathies. We have developed exidavnemab (BAN0805), a monoclonal antibody with…Safety and Efficacy of Sublingual Apomorphine in Parkinson’s Patients with or without Concomitant Dopamine Agonists Use
Objective: This post-hoc analysis of Study CTH-301 aimed to assess the safety and efficacy of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease with…Using Algorithm Guided Programming to Treat Parkinson’s Disease Patients Implanted with Deep Brain Stimulation
Objective: To compare acute outcomes from Parkinson’s disease patients implanted with Deep Brain Stimulation (DBS) programmed using Algorithm Guided Programming (AGP) versus conventional, standard of…Gender Differences Following Bilateral STN DBS Surgery in Parkinson’s Disease
Objective: To examine DBS surgery outcomes within the Deep Brain Stimulation (DBS) PD cohort at the NIH among males and females and improve our understanding…Evaluating Clinical Practices of General Neurologists and Movement Disorder Specialists Based on 2020 AAN Parkinson Disease Quality Metrics
Objective: To evaluate and compare clinical practices of providers caring for patients with Parkinson’s disease utilizing searchable proxies of published quality metrics. Background: In 2020,…Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease
Objective: Explore metabolic modulation as a disease-modifying target for inflammation in PRKN-PD Background: The release of mitochondrial DNA (mtDNA) is a well-documented phenotype in PRKN-linked…Single cell transcriptomics of peripheral blood mononuclear cells and associations with clinical outcomes in Parkinson’s disease
Objective: To assess transcriptomics signatures for monocytes and T-cells in different stages of Parkinson’s disease (PD) compared to controls and possible correlations with clinical outcomes.…Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study
Objective: To describe the effects of bemdaneprocel on motor and non-motor outcomes in participants with Parkinson’s disease (PD) up to 24 months post transplantation (12…Quantification of Neuroinflammation and White Matter Injury in Parkinson Disease Using Diffusion Basis Spectrum Imaging
Objective: To investigate differences in white matter (WM) using Diffusion Basis Spectrum Imaging (DBSI) between participants with Parkinson’s disease (PD) and controls and to examine…Cerebrovascular Reactivity and Glymphatic Clearance in Parkinson’s disease
Objective: To evaluate whether altered cerebrovascular reactivity contributes to reduced glymphatic clearance in Parkinson’s disease (PD). Background: Cerebrovascular activity is a major factor driving cerebrospinal…
- « Previous Page
- 1
- …
- 158
- 159
- 160
- 161
- 162
- …
- 436
- Next Page »